Lacosamide API

Name	Lacosamide
Chinese name	拉考沙胺
Cas Number	175481-36-4
Source	India
Qualifications	-/-/-/-/-

As the first third-generation new anti-epileptic drug approved in the Chinese market in 11 years, Vipavate (Lacosamide Tablets) brings brand-new treatment options for patients with partial epileptic seizures with its new and unique points of action. It brings significant benefits to patients who still cannot achieve good seizure control. Lacosamide is a new type of N-methyl-D-aspartate (NMDA) receptor glycine site binding antagonist. Different from other anti-epileptic drugs currently on the market in their mechanism of action, they selectively act on slow inactivation of sodium channels and prolong the time of sodium channel inactivation, which can more effectively reduce sodium influx and reduce neuronal excitability. Lacosamide is the only clinical anti-epileptic drug that acts on the slow inactivation of sodium ion channels without affecting the rapid inactivation. It has a significant effect on the treatment of focal epilepsy and has high safety.

Hot Tags: lacosamide api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Vardenafil API, Pleasant API, Idebenone API, Troxagliptin Succinate API, Gabapentin API, Itraconazole Hydrochloride API

• Previous: Desogestrel API
• Next: Avanafil API